Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) EBITDA (2024 - 2025)

Historic EBITDA for Kairos Pharma (KAPA) over the last 2 years, with Q2 2025 value amounting to -$1.5 million.

  • Kairos Pharma's EBITDA fell 55585.59% to -$1.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.6 million, marking a year-over-year change of. This contributed to the annual value of -$2.3 million for FY2024, which is 3669.78% down from last year.
  • Latest data reveals that Kairos Pharma reported EBITDA of -$1.5 million as of Q2 2025, which was down 55585.59% from -$1.3 million recorded in Q1 2025.
  • In the past 5 years, Kairos Pharma's EBITDA ranged from a high of -$222000.0 in Q2 2024 and a low of -$1.5 million during Q2 2025